This article is more than 5 years old. Information may no longer be current.
VIDEO: Stereotactic ablative radiotherapy, nivolumab trial warrants further investigation
Click Here to Manage Email Alerts
CHICAGO — Further investigation is warranted regarding treatment with stereotactic ablative radiotherapy in combination with anti-PD-1 therapy for patients with advanced lung cancer, Makenzi Evangelist, MD, said at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology.
Aparna Hegde, MD, and colleagues evaluated the combination of stereotactic ablative radiotherapy plus nivolumab (Opdivo, Bristol-Myers Squibb) to determine OS and independent predictive factors for mortality in this patient population.
After a median follow-up of 14.6 months, patients treated with stereotactic ablative radiotherapy during treatment demonstrated superior survival outcomes compared with those who received radiotherapy before treatment or did not undergo radiotherapy.
“This just reiterates some of the findings that we are seeing in our practices, clinically, and some of the institutional reports about improved immune modulation when combining radiation with immunotherapy,” Evangelist, from New York Oncology Hematology, said. “We just need to know, how do we actually do that, so further investigation is being done.” – by Kristie L. Kahl
Reference:
Hegde A, et al. Abstract 3A.01. Presented at International Association for the Study of Lung Cancer Multidisciplinary Symposium in Thoracic Oncology; Sept. 14-16, 2017; Chicago.
Disclosure: Evangelist reports no relevant financial disclosures.